Table 3.
Select clinically valuable pancreatic cancer biomarkers
| Gene product | Target drug | Mechanism | Ref. |
| hENT1 | Gemcitabine | Nucleoside inhibitor, prevents DNA synthesis in cancer cells | [59-64] |
| TS/DPD | 5-FU/S-1 | Suicide inhibitor of TS, prevents DNA synthesis in cancer cells | [65-71] |
| EGFR | Erlotinib | Tyrosine kinase inhibitor, prevents EGFR-mediated cell cycle progression and cellular proliferation | [72-79] |
| CA 19-9 | N/A | N/A | [80-88] |
| SPARC | Nab-paclitaxel | Disruption of microtubule formation during mitosis | [12,89-94] |
| SMAD4 | N/A | Tumor suppression, initiation, and metastasis | [95-99] |
CA 19-9: Carbohydrate antigen 19-9; TS: Thymidylate synthase; hENT1: Human equilibrative nucleoside transporter-1; SPARC: Secreted protein acidic and rich in cysteine; EGFR: Epidermal growth factor receptor.